Supplementary Table II. Recurrence, final dose, and patient-borne cost outcomes after stepwise baricitinib tapering

Recurrence patterns, time to recurrence, final baricitinib dose, and patient-borne cost reductions according to tapering outcome. Data are presented as median (IQR) or n/N (%), unless otherwise indicated. Tapering failure was defined as recurrence requiring re-escalation to baricitinib 4 mg daily. On-drug success was defined as continued baricitinib use at a reduced dose without re-escalation to 4 mg daily at last follow-up; off-drug success was defined as discontinuation without re-escalation. Minor and major recurrence were defined as recurrent SALT scores of <5 and ≥5, respectively, and percentages were calculated among patients with recurrence within each column. Time to recurrence was summarized among patients with recurrence. Final dose distributions were calculated among tapering successes. Cost estimates are specific to Korean drug pricing and reimbursement conditions. Per-patient cost reduction was calculated as [1 − actual patient-borne baricitinib cost / estimated patient-borne cost assuming uninterrupted 4-mg daily treatment over the same period] × 100; per-patient absolute cost saving was calculated as the corresponding cost difference. Costs are reported in Korean won (KRW). For reference, US$1 = KRW 1,477.93 on April 30, 2026. Unit costs were KRW 20,172 for a 4-mg tablet, approximately US$13.65, and KRW 13,448 for a 2-mg tablet, approximately US$9.10. Tapering costs were calculated according to each patient’s actual prescribed dosing schedule. Values are descriptive. Abbreviations: IQR, interquartile range; KRW, Korean won; NA, not applicable.本数据集涵盖基于减量治疗结局的复发模式、复发时间、巴瑞替尼（baricitinib）最终使用剂量以及患者自付成本降幅。除另有说明外，数据以中位数（四分位距IQR）或n/N（%）形式呈现。 减量治疗失败定义为疾病复发后需重新上调巴瑞替尼剂量至每日4mg。用药中成功定义为在末次随访时仍以减量后的剂量持续使用巴瑞替尼，未上调至每日4mg；停药成功定义为停用巴瑞替尼且未出现需上调剂量的复发情况。 轻度复发与重度复发分别定义为复发时的皮肤红斑狼疮面积与严重程度指数（SALT，Severity of Cutaneous Lupus Erythematosus Area and Severity Index）评分<5分和≥5分，各组复发患者的占比按列计算。复发时间仅在复发患者中进行汇总分析。最终剂量分布情况仅在减量治疗成功的患者中统计。 成本估算基于韩国药品定价与医保报销政策制定。每位患者的成本降幅计算公式为：[1 − 实际承担的巴瑞替尼费用 / 假设同期持续每日使用4mg巴瑞替尼的估算患者自付费用] × 100；每位患者的绝对成本节约额为对应费用差值。 费用以韩元（KRW）为单位。供参考的汇率为2026年4月30日的1美元=1477.93韩元。单剂药品单价为：4mg片剂每剂20172韩元，约合13.65美元；2mg片剂每剂13448韩元，约合9.10美元。减量治疗的费用按每位患者实际的处方给药方案计算。所有数据均为描述性统计结果。 缩写说明：IQR（interquartile range）为四分位距；KRW（Korean won）为韩元；NA（not applicable）为不适用。